AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUN 19 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - The addition of nonprimed dendritic cells to the same site targeted by the MUC1 DNA vaccine enhanced immunity against lymphoma cells in a murine model, researchers in Japan report.
K. Kontani and colleagues at Shiga University of Medical Science in Japan immunized C57BL/6 mice with a DNA vaccine that encoded for MUC1 polypeptide. Upon challenge with EL4-muc, MUC1-transfected syngeneic lymphoma cells, the immunized mice rejected the tumors. However, the DNA vaccine was unable to prevent progression of tumor growth in EL4-muc tumor-bearing mice.
"This animal model is useful for developing DNA vaccine for anticancer immunotherapy," asserted Kontani and coauthors.
In an effort to enhance immunogenicity of the vaccine, the researchers isolated activated nonprimed dendritic cells from syngeneic mice. Tumor growth was significantly diminished and survival time was extended when the dendritic cells were simultaneously delivered to the same site of the EL4-muc tumor-bearing mice as the MUC1 DNA vaccine. Dendritic cells found at the vaccination site contained MUC1 antigen as did the nodes that held MUC1 DNA and dendritic cells.
Although the antibody titers were similar in both the mice vaccinated with only MUC1 DNA and the mice given MUC1 ...
Source: HighBeam Research, Nonprimed dendritic cells enhance immune response.(Brief Article)